{"id":"chf-4226-pmdi","safety":{"commonSideEffects":[{"rate":null,"effect":"Tremor"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Palpitations"},{"rate":null,"effect":"Dry mouth"},{"rate":null,"effect":"Nasopharyngitis"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"The drug delivers two complementary bronchodilators via pressurized metered-dose inhaler (pMDI): a LABA component that activates beta-2 adrenergic receptors to increase cAMP and relax airway smooth muscle, and a LAMA component that blocks M3 muscarinic receptors to prevent acetylcholine-induced bronchoconstriction. This dual mechanism provides sustained airway dilation and improved lung function in COPD patients.","oneSentence":"CHF 4226 is an inhaled dual bronchodilator combining a long-acting beta-2 agonist and long-acting muscarinic antagonist for maintenance treatment of chronic obstructive pulmonary disease.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T03:26:25.608Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic obstructive pulmonary disease (COPD) maintenance treatment"}]},"trialDetails":[{"nctId":"NCT00782535","phase":"PHASE2","title":"Safety and Efficacy Study of Treatment With Single Doses of CHF 4226 pMDI in Patients With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2008-12","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":20},{"nctId":"NCT00605891","phase":"PHASE2","title":"Dose Finding Study of CHF 4226 for Treating Patients With COPD","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2006-10","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":278},{"nctId":"NCT00640484","phase":"PHASE2","title":"Confirmatory Dose Finding Study of 2 Dosages of CHF 4226 pMDI (Carmoterol) in Patients With COPD","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2008-04","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":57},{"nctId":"NCT00777595","phase":"PHASE1","title":"Evaluation of Possible Effects on the QTc Interval of CHF 4226 pMDI in Healthy Volunteers","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2008-10","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":47}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Carmoterol HFA"],"phase":"phase_2","status":"active","brandName":"CHF 4226 pMDI","genericName":"CHF 4226 pMDI","companyName":"Chiesi Farmaceutici S.p.A.","companyId":"chiesi-farmaceutici-s-p-a","modality":"Small molecule","firstApprovalDate":"","aiSummary":"CHF 4226 pMDI is a small molecule beta-2 adrenergic receptor agonist used to treat Chronic Obstructive Pulmonary Disease. It is administered via a pressurized metered-dose inhaler (pMDI) and has been studied in clinical trials for its effects on the QTc interval in healthy volunteers.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}